AbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire global rights to GUB014295, a long-acting amylin analogue developed by Danish biotech Gubra. Announced ...

AbbVie has joined the ranks of pharma groups trying to develop weight-loss drugs, licensing a long-acting amylin analogue from Denmark's Gubra in a deal valued at more than $2.2 billion.

AbbVie has signed a licensing deal with Danish-based Gubra to develop an obesity drug, marking the North Chicago company's first foray into the obesity market. Gubra will receive $350 million ...

Gubra’s first quarter was defined by the landmark exclusive global license agreement with AbbVie for GUBamy, a long-acting amylin analogue for obesity treatment.

Introduction & Market Context. Gubra AS (NASDAQ COPENHAGEN:GUBRA) presented its first quarter 2025 results on May 9, highlighting a transformative partnership with AbbVie (NYSE: ABBV) and progress in ...